Table 2.

Clinical and histologic characteristics of the independent set of patients with PTX3 serum evaluation

BPH (n = 61)Prostate cancer (n = 56)P
Age, y61.5 ± 10.465.6 ± 6.60.2
Suspicious DRE (%)29.537.50.4
Prostate volume (mL)59.3 ± 20.955.9 ± 13.80.7
Total PSA levels (ng/mL)7.5 ± 3.78.3 ± 4.40.7
PSA density (ng/mL*mL)0.4 ± 0.10.7 ± 0.30.5
International Prostate Symptom Score (I-PSS)10.8 ± 8.113.1 ± 9.60.6
Flow max (mL/s)15.0 ± 9.311.7 ± 7.30.1
Post-void residual (mL)42.3 ± 21.533.0 ± 18.70.7
Histologic grading of prostatic inflammation (G≥2)15/61 (24.5%)18/56 (34.1%)0.6
Aggressiveness of prostatic inflammation (A≥2)9/61 (14.7%)11/56 (19.6%)0.4
Biopsy Gleason score
 ≤635 (62.5%)
 713 (23.2%)
 ≥88 (14.3%)